- EnteroMedics Inc ETRM shares surged 73.3 percent to $6.88. EnteroMedics shares have jumped 120.56 percent over the past 52 weeks, while the S&P 500 index has gained 14.01 percent in the same period.
- SunLink Health Systems, Inc. SSY shares jumped 30.4 percent to $1.46. SunLink Health announced plans to buyback 3 million shares at $1.50 per share.
- Zafgen Inc ZFGN shares jumped 21.2 percent to $4.06g after gaining 0.60 percent on Thursday.
- Quotient Ltd QTNT shares gained 16.7 percent to $6.29 after the company reported positive MosaiQ results from its performance evaluation study.
- Stemline Therapeutics Inc STML shares climbed 14.2 percent to $12.96 after the company reported a FDA deal on expedited pathway to full approval of SL-401 in first-line BPDCN.
- Pacira Pharmaceuticals Inc PCRX shares surged 14.2 percent to $39.00. Pacira Pharmaceuticals reported preliminary 2016 revenue of $276.4 million.
- Cempra Inc CEMP shares gained 12.3 percent to $3.65.
- Abeona Therapeutics Inc ABEO climbed 6.7 percent to $5.97. Jefferies initiated coverage on Abeona Therapeutics with a Buy rating.
- Healthways, Inc. HWAY shares rose 6.5 percent to $24.75. Jefferies upgraded Healthways from Hold to Buy.
- Helen of Troy Limited HELE shares climbed 6.4 percent to $95.00. Helen of Troy reported better-than-expected earnings for its third quarter, but sales missed expectations. The company raised its earnings forecast for the year, but lowered its sales outlook.
- Ionis Pharmaceuticals Inc IONS shares gained 5.5 percent to $49.66 after the company reported a licensing deal with Novartis AG (ADR) NVS.
- CTI BioPharma Corp CTIC shares rose 4.5 percent to $4.66 after surging 12.34 percent on Thursday.
- Neurocrine Biosciences, Inc. NBIX shares rose 4.4 percent to $43.19. Neurocrine issued an update on FDA Advisory Committee for INGREZZA for the treatment of tardive dyskinesia.
- Amgen, Inc. AMGN rose 3.3 percent to $157.96 after the company disclosed that it has won a court ruling for a ban on Sanofi's sales of praluent cholestrol drug.
- Gap Inc GPS rose 2.4 percent to $23.80. Gap reported a 2 percent year-over-year gain in its comparable sales for the November and December 2016 holiday season. Gap comparable sales for December rose 4 percent, compared to a 5 percent decline last year.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
